Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN)

Q: What does CUSIP 92840H400 represent in this 13F holders report?

CUSIP 92840H400 is the security identifier for VTGN - Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held VTGN - Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q2 2025?

50 institutional investors reported VTGN - Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q2 2025. Use the holders table for investor-level position and value details.

CUSIP: 92840H400

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 39,040,476
Total 13F shares: 14,875,235
Share change: -449,833
Total reported value: $29,750,933
Put/Call ratio: 53%
Price per share: $2.00
Number of holders: 50
Value change: -$917,939
Number of buys: 22
Number of sells: 15

Quarterly Holders Quick Answers

What is CUSIP 92840H400?
CUSIP 92840H400 identifies VTGN - Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025
Previous quarter: Q1 2025

Recent filing periods for CUSIP 92840H400:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of VTGN - Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Venrock Healthcare Capital Partners II, L.P.	3/4/5	10%+ Owner	— class O/S missing	20,637,286	$35,434,220	—	12 Jul 2022	3/4/5
BIOTECHNOLOGY VALUE FUND L P	13D/G	BVF PARTNERS L P/IL	10%	3,084,324	$7,217,318	$0	31 Dec 2024	13D/G
TCG Crossover Management, LLC	13F	Company	6.9%	2,676,580	$6,691,451	—	31 Mar 2025	13F
STEMPOINT CAPITAL LP	13F	Company	6.1%	2,366,554	$5,111,689	—	31 Mar 2025	13F
Nantahala Capital Management, LLC	13F	Company	5.1%	1,978,492	$4,946,230	—	31 Mar 2025	13F
VANGUARD GROUP INC	13F	Company	5%	1,960,172	$4,900,431	—	31 Mar 2025	13F
Commodore Capital LP	13F 3/4/5	Company · 10%+ Owner	4%	1,575,000	$3,937,500	—	31 Mar 2025	13F 3/4/5
SPHERA FUNDS MANAGEMENT LTD.	13F	Company	2%	790,550	$1,976,375	—	31 Mar 2025	13F
JPMORGAN CHASE & CO	13F	Company	1.9%	750,876	$1,877,190	—	31 Mar 2025	13F
Ikarian Capital, LLC	13F	Company	1.5%	601,703	$1,504,259	—	31 Mar 2025	13F
DIADEMA PARTNERS LP	13F	Company	1.4%	565,975	$1,414,938	—	31 Mar 2025	13F
ADAR1 Capital Management, LLC	13F	Company	1.1%	420,765	$1,051,912	—	31 Mar 2025	13F
BlackRock, Inc.	13F	Company	1.1%	416,338	$1,040,846	—	31 Mar 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.69%	270,187	$675,753	—	31 Mar 2025	13F
Almitas Capital LLC	13F	Company	0.65%	254,655	$636,638	—	31 Mar 2025	13F
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	0.46%	177,858	$444,645	—	31 Mar 2025	13F
BML Capital Management, LLC	13F	Company	0.38%	150,000	$375,000	—	31 Mar 2025	13F
AdvisorShares Investments LLC	13F	Company	0.41%	159,114	$372,327	—	31 Mar 2025	13F
Persistent Asset Partners Ltd	13F	Company	0.31%	121,651	$304,128	—	31 Mar 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.29%	112,507	$281,268	—	31 Mar 2025	13F
BLAIR WILLIAM & CO/IL	13F	Company	0.26%	100,866	$252,165	—	31 Mar 2025	13F
STATE STREET CORP	13F	Company	0.25%	96,858	$242,145	—	31 Mar 2025	13F
H. Ralph Snodgrass	3/4/5	PRES./CHIEF SCIENTIFIC OFFICER	— class O/S missing	98,859	$169,741	—	31 Dec 2021	3/4/5
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.17%	64,781	$161,953	—	31 Mar 2025	13F
MORGAN STANLEY	13F	Company	0.13%	51,285	$128,213	—	31 Mar 2025	13F
NORTHERN TRUST CORP	13F	Company	0.12%	48,093	$120,233	—	31 Mar 2025	13F
AMERICAN CENTURY COMPANIES INC	13F	Company	0.08%	31,063	$77,658	—	31 Mar 2025	13F
Prosperity Wealth Management, Inc.	13F	Company	0.07%	27,600	$69,000	—	31 Mar 2025	13F
UBS Group AG	13F	Company	0.07%	25,779	$64,448	—	31 Mar 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.06%	24,800	$62,000	—	31 Mar 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.06%	23,302	$58,255	—	31 Mar 2025	13F
HighTower Advisors, LLC	13F	Company	0.05%	20,828	$52,070	—	31 Mar 2025	13F
Kestra Advisory Services, LLC	13F	Company	0.05%	20,033	$50,083	—	31 Mar 2025	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.04%	17,545	$43,863	—	31 Mar 2025	13F
Mark Alan Smith	3/4/5	CHIEF MEDICAL OFFICER	— class O/S missing	19,915	$34,194	—	30 Jun 2022	3/4/5
TWO SIGMA ADVISERS, LP	13F	Company	0.03%	10,732	$26,830	—	31 Mar 2025	13F
Cubist Systematic Strategies, LLC	13F	Company	0.03%	10,088	$25,220	—	31 Mar 2025	13F
Cynthia Lynn Anderson	3/4/5	CHIEF FINANCIAL OFFICER	— mixed-class rows	112,801 mixed-class rows	$21,761	—	30 Jun 2025	3/4/5
GROUP ONE TRADING LLC	13F	Company	0.01%	5,569	$13,922	—	31 Mar 2025	13F
OSAIC HOLDINGS, INC.	13F	Company	0.01%	5,494	$13,734	—	31 Mar 2025	13F
Jerrold Duane Dotson	3/4/5	VP, CFO	— class O/S missing	3,671	$6,303	—	30 Jun 2023	3/4/5
SIMPLEX TRADING, LLC	13F	Company	0.01%	2,402	$6,000	—	31 Mar 2025	13F
CWM, LLC	13F	Company	0%	1,582	$4,000	—	31 Mar 2025	13F
Performa Ltd (US), LLC	13F	Company	0%	1,000	$2,500	—	31 Mar 2025	13F
ROYAL BANK OF CANADA	13F	Company	0%	911	$2,000	—	31 Mar 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	677	$1,692	—	31 Mar 2025	13F
MAI Capital Management	13F	Company	0%	576	$1,440	—	31 Mar 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0%	471	$1,178	—	31 Mar 2025	13F
SBI Securities Co., Ltd.	13F	Company	0%	286	$715	—	31 Mar 2025	13F
SJS Investment Consulting Inc.	13F	Company	0%	100	$250	—	31 Mar 2025	13F

Institutional Holders of Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) as of Q2 2025

As of 30 Jun 2025, Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) was held by 50 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 14,875,235 shares. The largest 10 holders included TCG Crossover Management, LLC, Nantahala Capital Management, LLC, STEMPOINT CAPITAL LP, VANGUARD GROUP INC, Commodore Capital LP, JPMORGAN CHASE & CO, Ikarian Capital, LLC, SPHERA FUNDS MANAGEMENT LTD., ADAR1 Capital Management, LLC, and BlackRock, Inc.. This page lists 51 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

Q2 2025 holders

Holder diff

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.